![Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study | The BMJ Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study | The BMJ](https://www.bmj.com/content/bmj/378/bmj-2022-070483/F2.large.jpg)
Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study | The BMJ
![Vaccines | Free Full-Text | Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2 Vaccines | Free Full-Text | Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2](https://www.mdpi.com/vaccines/vaccines-10-02146/article_deploy/html/images/vaccines-10-02146-g001a.png)
Vaccines | Free Full-Text | Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2
![Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines: Expert Review of Vaccines: Vol 22, No 1 Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines: Expert Review of Vaccines: Vol 22, No 1](https://www.tandfonline.com/action/showGraphicalAbstractImage?doi=10.1080%2F14760584.2023.2232020&id=ierv_a_2232020_uf0001_oc.jpg)
Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines: Expert Review of Vaccines: Vol 22, No 1
![Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study - The Lancet Global Health Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study - The Lancet Global Health](https://www.thelancet.com/cms/attachment/b7470a81-2935-4740-9fb4-c532d912c682/gr1_lrg.gif)
Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study - The Lancet Global Health
![Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study - The Lancet Regional Health – Europe Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study - The Lancet Regional Health – Europe](https://www.thelancet.com/cms/attachment/ec8132af-622c-4cda-bd8d-1f61c6ca2606/gr1_lrg.jpg)
Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study - The Lancet Regional Health – Europe
Sano y salvo on X: "Declaración conjunta de la @EMA_News y el @ECDC_EU sobre la posibilidad de usar dos vacunas #COVID19 diferentes, tanto para las dos primeras dosis como para la tercera
![COVID-19: safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine (Sputnik V) COVID-19: safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine (Sputnik V)](https://www.pcronline.com/var/pcrov3/storage/images/media/pcr/news/2021/sputnik-vaccine/14187886-1-eng-GB/sputnik-vaccine_imagefull.jpg)
COVID-19: safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine (Sputnik V)
![Study shows enhanced immunogenicity of heterologous boosting strategy in individuals primed with J&J vaccine Study shows enhanced immunogenicity of heterologous boosting strategy in individuals primed with J&J vaccine](https://d2jx2rerrg6sh3.cloudfront.net/image-handler/picture/2021/10/shutterstock_1901384401-1.jpg)
Study shows enhanced immunogenicity of heterologous boosting strategy in individuals primed with J&J vaccine
![Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 - The Lancet Infectious Diseases Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/4f775784-4453-4c08-98f1-01483f865da7/gr1_lrg.jpg)
Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 - The Lancet Infectious Diseases
![Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study - The Lancet Respiratory Medicine Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study - The Lancet Respiratory Medicine](https://www.thelancet.com/cms/asset/b9c057e0-e68d-4608-9700-73b19be518ae/gr1.jpg)
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study - The Lancet Respiratory Medicine
![Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine - ScienceDirect Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0753332222000385-ga1.jpg)
Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine - ScienceDirect
![Vaccines | Free Full-Text | Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2 Vaccines | Free Full-Text | Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2](https://pub.mdpi-res.com/vaccines/vaccines-10-02146/article_deploy/html/images/vaccines-10-02146-g002.png?1671532641)
Vaccines | Free Full-Text | Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2
![Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet](https://www.thelancet.com/cms/attachment/55458d8a-6e53-43a3-abb0-e72e5acba138/gr1.gif)
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet
![Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant | Signal Transduction and Targeted Therapy Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant | Signal Transduction and Targeted Therapy](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41392-022-01062-3/MediaObjects/41392_2022_1062_Fig1_HTML.png)
Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant | Signal Transduction and Targeted Therapy
Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
Strategies and safety considerations of booster vaccination in COVID-19 | Biomolecules and Biomedicine
![Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial - The Lancet Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial - The Lancet](https://www.thelancet.com/cms/asset/3b4eb078-d7dd-4a37-98ea-553c444f2a49/gr1.jpg)
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial - The Lancet
![Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial - The Lancet Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial - The Lancet](https://www.thelancet.com/cms/asset/f37e5492-b6e5-43dd-9400-1478e6cbe180/gr1.jpg)
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial - The Lancet
![Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination | Nature Medicine Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-022-01705-6/MediaObjects/41591_2022_1705_Fig1_HTML.png)